Milestone Scientific Inc. (NYSEAMERICAN:MLSS)‘s stock had its “buy” rating restated by investment analysts at Maxim Group in a research note issued on Wednesday. They presently have a $4.00 price objective on the medical instruments supplier’s stock. Maxim Group’s target price points to a potential upside of 207.69% from the company’s previous close.

The analysts wrote, “3Q17 revenue of $2.85M, down 10.4% y/y, was slightly above our estimate of $2.74M.””

Separately, ValuEngine raised shares of Milestone Scientific from a “sell” rating to a “hold” rating in a research report on Friday, September 8th.

Shares of Milestone Scientific (NYSEAMERICAN MLSS) traded up $0.05 during midday trading on Wednesday, reaching $1.30. 33,400 shares of the company traded hands, compared to its average volume of 34,382. Milestone Scientific has a one year low of $1.08 and a one year high of $2.15.

WARNING: “Milestone Scientific Inc. (MLSS) Rating Reiterated by Maxim Group” was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at

Milestone Scientific Company Profile

Milestone Scientific Inc (Milestone) is engaged in providing computer-controlled injection technologies and solutions for the medical and dental markets. The Company uses its CompuFlo technology for the delivery of medicaments. The CompuFlo pressure or force Computer-Controlled Local Anesthetic Delivery (C-CLAD) technology is a medical technology for the delivery of drugs, anesthetics and other medicaments into various tissue types.

Receive News & Ratings for Milestone Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Scientific Inc. and related companies with's FREE daily email newsletter.